Trending Now
Chimerix (NASDAQ: CMRX) Announces Publication of ONC201 Findings From Phase 2...
Chimerix (NASDAQ: CMRX) has announced the publication of a peer-reviewed article entitled, "Phase 2 Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma (PC-PG) and...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) Announce Expanded Access For Berotralstat In HAE...
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) established expanded access program (EAP) for its investigational drug berotralsat in the treatment of hereditary angioedema (HAE)patients in the US.
Berotralstat...
MAKE IT MODERN
LATEST REVIEWS
miRagen Therapeutics Inc. (NASDAQ:MGEN) To Halt Development Of Cobomarsen After SOLAR...
miRagen Therapeutics Inc. (NASDAQ:MGEN) has announced that it is carrying an internal review of initial topline data from the second phase SOLAR clinical study...
MAKE IT MODERN
PERFORMANCE TRAINING
Could AppTech Payments Corp (NASDAQ:APCX) Dominate All Digital Payments ?
With all the financial technology out there, why is moving money from person to person, business to business, or paying for goods...
Gilead Sciences Inc. (NASDAQ:GILD) Receives FDA Approval For Remdesivir In Treating COVID-19
The US FDA has approved Gilead Sciences Inc. (NASDAQ:GILD) antiviral therapy remdesivir for the treatment of COVID-19. This makes the drug the first to...
FDA approval could spark huge interest in Mainz Biomed (NASDAQ:MYNZ)
Colorectal cancer (CRC) is the second most lethal cancer in the U.S. and Europe, but also the most preventable with early detection...
Ocular Therapeutix™ (NASDAQ:OCUL) Report Net Revenue Of $5.9 Million In Q3 2020 Driven By...
Ocular Therapeutix™ (NASDAQ:OCUL) has announced its Q3 2020 financial results in which DEXTENZA® net product revenue was up 280% QoQ and also provided its...
TRACON Pharmaceuticals (NASDAQ: TCON) Announces Independent Data Monitoring Committee For ENVASARC Pivotal Study
TRACON Pharmaceuticals (NASDAQ: TCON) has confirmed the Independent Data Monitoring Committee for its current ENVASARC pivotal study recommended for the ongoing accrual as planned...
MAKE IT MODERN
